Document Detail

High-dose Methylprednisolone for Veno-occlusive Disease of the Liver in Pediatric Hematopoietic Stem Cell Transplant Recipients.
MedLine Citation:
PMID:  23211838     Owner:  NLM     Status:  Publisher    
Veno-occlusive disease (VOD) of the liver is a well-recognized serious complication of hematopoietic stem cell transplantation (HSCT) with few successful treatment modalities available for severe disease. While there have been some reports demonstrating success in adults with high dose steroid therapy, experience in the pediatric population is lacking. We retrospectively reviewed HSCT patients treated at our institution since 2003 and identified 15 (2.4%) who developed VOD. Of these 9 (60%) were treated with high-dose Methylprednisolone (500 mg/m(2)/dose IV every 12 hours for 6 doses). Steroid therapy was initiated at or prior to first ultrasound evidence of reversal of portal venous flow, and prior to meeting criteria for initiation of defibrotide therapy. Four of the patients were also treated with defibrotide starting 2 to 5 days following initiation of steroids. Eight of 9 patients (88%) with VOD were diagnosed with multi-organ failure (MOF). Response to high dose steroid therapy as defined by decrease in bilirubin by 50% by ten days from therapy initiation was noted in 6/9 (67%) patients, occurring within 3 to 6 days of steroid therapy. Two patients died due to VOD with MOF. Seven survivors of VOD recovered from VOD at the median 6 days (range 5-38) from VOD diagnosis. Overall VOD survival as a group was 78% however survival amongst responders was 100%. No serious toxicities related to high dose steroid therapy were observed. We conclude that high dose steroid therapy if initiated early may reverse VOD of the liver in pediatric HSCT patients, abrogating the need for defibrotide therapy with its associated toxicities and regulatory difficulties.
Kasiani C Myers; Julia Lawrence; Rebecca A Marsh; Stella M Davies; Sonata Jodele
Related Documents :
25061508 - Rload: does sex mediate the effect of acute antiplatelet loading on stroke outcome.
24416138 - A phase i, dose-finding study of sorafenib in combination with gemcitabine and radiatio...
25109798 - The coag and eu-pact trials: what is the clinical benefit of pharmacogenetic-guided cou...
22049278 - Effect of five common anticonvulsant drugs on naloxone-precipitated morphine withdrawal...
23431958 - Comparison of oral ivermectin versus crotamiton 10% cream in the treatment of scabies.
6625078 - Albendazole, an effective single dose, broad spectrum anthelmintic drug.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-1
Journal Detail:
Title:  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation     Volume:  -     ISSN:  1523-6536     ISO Abbreviation:  Biol. Blood Marrow Transplant.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9600628     Medline TA:  Biol Blood Marrow Transplant     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA. Electronic address:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ipilimumab activity in advanced uveal melanoma.
Next Document:  Ultrasound elastography in the evaluation of thyroid nodules for thyroid cancer.